Cargando…

Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy

We compared lesion-based sensitivity of dual-time-point FDG-PET/CT, bone scintigraphy (BS), and low-dose CT (LDCT) for detection of various types of bone metastases in patients with metastatic breast cancer. Prospectively, we included 18 patients with recurrent breast cancer who underwent dual-time-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Jeanette Ansholm, Naghavi-Behzad, Mohammad, Gerke, Oke, Baun, Christina, Falch, Kirsten, Duvnjak, Sandra, Alavi, Abass, Høilund-Carlsen, Poul Flemming, Hildebrandt, Malene Grubbe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601566/
https://www.ncbi.nlm.nih.gov/pubmed/34793550
http://dx.doi.org/10.1371/journal.pone.0260066
_version_ 1784601383042809856
author Hansen, Jeanette Ansholm
Naghavi-Behzad, Mohammad
Gerke, Oke
Baun, Christina
Falch, Kirsten
Duvnjak, Sandra
Alavi, Abass
Høilund-Carlsen, Poul Flemming
Hildebrandt, Malene Grubbe
author_facet Hansen, Jeanette Ansholm
Naghavi-Behzad, Mohammad
Gerke, Oke
Baun, Christina
Falch, Kirsten
Duvnjak, Sandra
Alavi, Abass
Høilund-Carlsen, Poul Flemming
Hildebrandt, Malene Grubbe
author_sort Hansen, Jeanette Ansholm
collection PubMed
description We compared lesion-based sensitivity of dual-time-point FDG-PET/CT, bone scintigraphy (BS), and low-dose CT (LDCT) for detection of various types of bone metastases in patients with metastatic breast cancer. Prospectively, we included 18 patients with recurrent breast cancer who underwent dual-time-point FDG-PET/CT with LDCT and BS within a median time interval of three days. A total of 488 bone lesions were detected on any of the modalities and were categorized by the LDCT into osteolytic, osteosclerotic, mixed morphologic, and CT-negative lesions. Lesion-based sensitivity was 98.2% (95.4–99.3) and 98.8% (96.8–99.5) for early and delayed FDG-PET/CT, respectively, compared with 79.9% (51.1–93.8) for LDCT, 76.0% (36.3–94.6) for BS, and 98.6% (95.4–99.6) for the combined BS+LDCT. BS detected only 51.2% of osteolytic lesions which was significantly lower than other metastatic types. SUVs were significantly higher for all lesion types on delayed scans than on early scans (P<0.0001). Osteolytic and mixed-type lesions had higher SUVs than osteosclerotic and CT-negative metastases at both time-points. FDG-PET/CT had significantly higher lesion-based sensitivity than LDCT and BS, while a combination of the two yielded sensitivity comparable to that of FDG-PET/CT. Therefore, FDG-PET/CT could be considered as a sensitive one-stop-shop in case of clinical suspicion of bone metastases in breast cancer patients.
format Online
Article
Text
id pubmed-8601566
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-86015662021-11-19 Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy Hansen, Jeanette Ansholm Naghavi-Behzad, Mohammad Gerke, Oke Baun, Christina Falch, Kirsten Duvnjak, Sandra Alavi, Abass Høilund-Carlsen, Poul Flemming Hildebrandt, Malene Grubbe PLoS One Research Article We compared lesion-based sensitivity of dual-time-point FDG-PET/CT, bone scintigraphy (BS), and low-dose CT (LDCT) for detection of various types of bone metastases in patients with metastatic breast cancer. Prospectively, we included 18 patients with recurrent breast cancer who underwent dual-time-point FDG-PET/CT with LDCT and BS within a median time interval of three days. A total of 488 bone lesions were detected on any of the modalities and were categorized by the LDCT into osteolytic, osteosclerotic, mixed morphologic, and CT-negative lesions. Lesion-based sensitivity was 98.2% (95.4–99.3) and 98.8% (96.8–99.5) for early and delayed FDG-PET/CT, respectively, compared with 79.9% (51.1–93.8) for LDCT, 76.0% (36.3–94.6) for BS, and 98.6% (95.4–99.6) for the combined BS+LDCT. BS detected only 51.2% of osteolytic lesions which was significantly lower than other metastatic types. SUVs were significantly higher for all lesion types on delayed scans than on early scans (P<0.0001). Osteolytic and mixed-type lesions had higher SUVs than osteosclerotic and CT-negative metastases at both time-points. FDG-PET/CT had significantly higher lesion-based sensitivity than LDCT and BS, while a combination of the two yielded sensitivity comparable to that of FDG-PET/CT. Therefore, FDG-PET/CT could be considered as a sensitive one-stop-shop in case of clinical suspicion of bone metastases in breast cancer patients. Public Library of Science 2021-11-18 /pmc/articles/PMC8601566/ /pubmed/34793550 http://dx.doi.org/10.1371/journal.pone.0260066 Text en © 2021 Hansen et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hansen, Jeanette Ansholm
Naghavi-Behzad, Mohammad
Gerke, Oke
Baun, Christina
Falch, Kirsten
Duvnjak, Sandra
Alavi, Abass
Høilund-Carlsen, Poul Flemming
Hildebrandt, Malene Grubbe
Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
title Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
title_full Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
title_fullStr Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
title_full_unstemmed Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
title_short Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
title_sort diagnosis of bone metastases in breast cancer: lesion-based sensitivity of dual-time-point fdg-pet/ct compared to low-dose ct and bone scintigraphy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601566/
https://www.ncbi.nlm.nih.gov/pubmed/34793550
http://dx.doi.org/10.1371/journal.pone.0260066
work_keys_str_mv AT hansenjeanetteansholm diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy
AT naghavibehzadmohammad diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy
AT gerkeoke diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy
AT baunchristina diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy
AT falchkirsten diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy
AT duvnjaksandra diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy
AT alaviabass diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy
AT høilundcarlsenpoulflemming diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy
AT hildebrandtmalenegrubbe diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy